medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2017, Number 4

<< Back Next >>

Ann Hepatol 2017; 16 (4)

Liver Biopsy in Chronic Liver Diseases: Is There a Favorable Benefit: Risk Balance?

Larrey D, Meunier L, Ursic-Bedoya J

Language: English
References: 15
Page: 487-489
PDF size: 109.91 Kb.


ABSTRACT

Liver biopsy is still useful in selected clinical situations in which it is the only tool to obtain information necessary for the diagnosis, the prognosis, and the decision for treatment. Main examples are viral hepatitis with confounding co-morbidities, non alcoholic fatty liver disease, and autoimmune liver diseases.


REFERENCES

  1. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Eng J Med 2001; 344: 495-500.

  2. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology 2009; 49: 1017-44.

  3. Cadranel JF, Nosbam JB, Gouillou Maelen Hanslik B. Major changes in the number and indications of liver biopsy for chronic liver diseases over one decade in France. Eur J Gastroenterol Hepatol 2016; 28: 26-32.

  4. Castera L. Noninvasive methods to assess liver disease in patients with hepatitis b and C. Gastroenterology 2012; 142: 1293-302.

  5. European Association for Study of Liver, Asociacion Latino Americana par el Estudio del Higado. EASL Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015; 63: 237-64.

  6. EASL 2017 Clinical practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017 (in press).

  7. EASL Clinical practical Guidelines: management of Alcoholic Liver Disease. J Hepatol 2012; 57: 399-420.

  8. Fonseca J, Nunes G, Fonseca C, Canhato M, Barata AT, Santos CA. EASL-EASD-EASO Clinical practice Guidelines for the mangement of non-alcoholic fatty liver disease. J Hepatol 2016; 64: 1388-402.

  9. EASL Clinical Practice Guidelines: Autoimmune hepatitis. J Hepatol 2015; 63: 971-1004.

  10. EASL Clinical Practice Guidelines: The diagnosis and mangement of patients with primary biliary cholangitis. J Hepatol 2017 (in press).

  11. European Association for the Study of the Liver. EASL Clinical practice Guidelines for HFE Hemochromatosis. J Hepatol 2010; 53: 3-22.

  12. Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, Hunt CM, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011; 89: 806-15.

  13. Lebrec D, Goldfarb G, Degoot C, Rueff B, Benhamou JP. Transvenous liver biopsy: an experience based on 1000 hepatic tissue samplings with this procedure. Gastroenterology 1982; 83: 338-40.

  14. Regev A, Berho M, Jeffers L, Milkowski C, Molina EG, Pyrsocoulos NT, Feng ZZ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-18.

  15. European Association for the Study of the Liver. EASL recommendations on treament of hepatitis C 2016. J Hepatol 2017; 66: 153-97.




2020     |     www.medigraphic.com